The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!
On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the European Commission (EC) has approved the approval of the orphan drug product Isturia (osilodrostat) for the treatment of endogenous Cushing's syndrome ).
Isturia's active pharmaceutical ingredient is osilodrostat, a cortisol synthesis inhibitor that works by inhibiting 11-β hydroxylase, which is responsible for the final step of adrenal cortisol biosynthesis. Isturia will provide 1 mg, 5 mg, and 10 mg film-coated tablets.
The advantage of Isturia is that it can control or normalize cortisol levels in adult CS patients, and has manageable safety, making this product a valuable treatment option for CS patients.